Skip to main content

Table 1 Baseline characteristics and clinical outcomes of ATTAIN study patients with Staphylococcus aureus nosocomial pneumonia according to vancomycin trough levels

From: Effect of vancomycin serum trough levels on outcomes in patients with nosocomial pneumonia due to Staphylococcus aureus: a retrospective, post hoc, subgroup analysis of the Phase 3 ATTAIN studies

  Vancomycin trough level (μg/mL),
n (%)*
p
  < 10 (n = 30) 10 to < 15 (n = 33) ≥ 15 (n = 35)  
Age (mean ± SD, year) 60 ± 20 69 ± 13 69 ± 14 0.14
APACHE II score (mean ± SD) 16 ± 5 17 ± 7 18 ± 6 0.45
Creatinine clearance ≤ 50 mL/min 10 (33) 18 (55) 14 (40) 0.22
Acute renal failure 2 (7) 5 (15) 10 (29) 0.06
Multilobar pneumonia 17 (57) 19 (58) 28 (80) 0.08
Bacteremia 6 (20) 2 (6) 2 (6) 0.10
Resident in ICU 20 (67) 24 (73) 28 (80) 0.48
Use of vasopressor/inotropic 5 (17) 5 (15) 7 (20) 0.87
Shock 2 (7) 2 (6) 4 (11) 0.68
Potentially nephrotoxic prior antibiotic therapy     
  Vancomycin 11 (37) 14 (42) 17 (49) 0.63
  Amikacin 1 (3) 1 (3) 2 (6) --
  Gentamicin 0 2 (6) 1 (3) --
Prior antibiotic failure 11 (37) 18 (55) 28 (80) 0.002
MRSA 20 (67) 26 (79) 30 (86) 0.18
Staphylococcus aureus MIC > 1 μg/mL 0 0 1 (3) 0.41
  1. APACHE II, Acute Physiology and Chronic Health Evaluation II; ATTAIN, Assessment of Telavancin for Treatment of Hospital-Acquired Pneumonia; ICU, intensive care unit; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant Staphylococcus aureus; SD, standard deviation.
  2. *Unless otherwise stated.
  3. Kruskall-Wallis or Cochran-Mantel-Haenszel general association.
  4. S. aureus recovered from baseline blood cultures.